Categories: News

Sharecare to present at 40th Annual J.P. Morgan Healthcare Conference

ATLANTA, Dec. 21, 2021 /PRNewswire/ — Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced that its chairman and CEO, Jeff Arnold, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022 at 2:15 p.m. EST.

A live audio webcast and replay of the event will be available online at https://investors.sharecare.com/news-and-events/events-and-presentations.

About Sharecare
Sharecare is the leading digital health company that helps people – no matter where they are in their health journey – unify and manage all their health in one place. Our comprehensive and data-driven virtual health platform is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. Driven by our philosophy that we are all together better, at Sharecare, we are committed to supporting each individual through the lens of their personal health and making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Relations:
Jen Martin Hall
jen@sharecare.com 

Investor Relations:
Evan Smith, CFA
evan.smith@sharecare.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/sharecare-to-present-at-40th-annual-jp-morgan-healthcare-conference-301448812.html

SOURCE Sharecare

Staff

Recent Posts

The Power of Tracking: New Preliminary Data Underscores How MyFitnessPal Supports Weight Management Goals

Research highlights how nutrition tracking drives success for weight loss and health goals NEW YORK,…

46 minutes ago

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

4 hours ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

4 hours ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

4 hours ago